

To:

emlsecretariat@who.int

UNIVERSITY MEDICAL Center
Schleswig-Holstein

Pediatrics I, Campus Kiel

Prof. Dr. Martin Schrappe

Administrative office

Gabi Marget

Phone

+49 (0) 431/ 500 20102

e-mail

m.schrappe@pediatrics.uni-kiel.de



Date: April 4, 2025

Subject: **Comment in Support of Blinatumomab for Inclusion in the WHO Model List of Essential Medicines for Children**

Dear WHO Expert Committee,

I am writing to express my strong support for the inclusion of **blinatumomab** on the **WHO Model List of Essential Medicines for Children (EMLc)**.

Blinatumomab has demonstrated significant clinical benefit in the treatment of **acute lymphoblastic leukemia** in children. As a bispecific T-cell engager, it provides a targeted and effective option for patients with poor prognosis, many of whom do not respond to conventional chemotherapy. Its inclusion on the EMLc would be a critical step toward improving access to this innovative therapy in low- and middle-income countries, where treatment options are often limited.

Including blinatumomab in the EMLc would align with the goals of the **WHO Global Initiative for Childhood Cancer (GICC)**, and help reduce survival disparities by ensuring that essential, high-impact cancer medicines are made more widely available.

I respectfully urge the Committee to give this application full consideration and to support the global effort to expand access to life-saving treatment for children with cancer.

Sincerely,

Prof. Dr. med. Martin Schrappe
-- Principal Investigator AIEOP-BFM ALL 2017 --